Recursion Pharmaceuticals is a biotechnology business based in the US. Recursion Pharmaceuticals shares (RXRX) are listed on the NASDAQ and all prices are listed in US Dollars. Its last market close was $6.49 – an increase of 11.13% over the previous week. Recursion Pharmaceuticals employs 800 staff and has a trailing 12-month revenue of around $59.8 million.
Terms and conditions apply*. For 401k rollovers, existing SoFi IRA members must complete 401k rollovers via this link For SoFi members without a SoFi IRA, a SoFi IRA must first be opened, and 401k rollover must be completed utilizing Capitalize via this link. SoFi and Capitalize will charge no additional fees to process a 401(k) rollover to a SoFi IRA. SoFi is not liable for any costs incurred from the existing 401k provider for rollover. Please check with your 401k provider for any fees or costs associated with the rollover. For IRA contributions, only deposits made via ACH and cash transfer from SoFi Bank accounts are eligible for the match. Click here for the 1% Match terms and conditions.
Must be a SoFi Plus member at the time a recurring deposit is received into your SoFi Active or Automated investing account to qualify. Bonus calculated on net monthly recurring deposits made via ACH and paid out as Rewards Points. See Rewards Terms of Service. SoFi reserves the right to change or terminate this promotion at any time without notice. See terms and limitations. https://www.sofi.com/sofiplus/invest/#disclaimers
Open an account.Provide your personal information and sign up.
Fund your account.Deposit funds into your account by linking your banking information or transfer funds from another trading account.
Search for the stock name – RXRX.Search for the stock by name or ticker symbol.
Buy the stock. Place your order. It's that simple.
Buy Recursion Pharmaceuticals stock from these online trading platforms
Compare special offers, low fees and a wide range of investment options among top trading platforms.
7 of 7
What is the Finder Score?
The Finder Score crunches 147 key metrics we collected directly from 18+ brokers and assessed each provider’s performance based on nine different categories, weighing each metric based on the expertise and insights of Finder’s investment experts. We then scored and ranked each provider to determine the best brokerage accounts.
We update our best picks as products change, disappear or emerge in the market. We also regularly review and revise our selections to ensure our best provider lists reflect the most competitive available.
Paid non-client promotion. Finder does not invest money with providers on this page. If a brand is a referral partner, we're paid when you click or tap through to, open an account with or provide your contact information to the provider. Partnerships are not a recommendation for you to invest with any one company. Learn more about how we make money.
Finder is not an advisor or brokerage service. Information on this page is for educational purposes only and not a recommendation to invest with any one company, trade specific stocks or fund specific investments. All editorial opinions are our own.
Is it a good time to buy Recursion Pharmaceuticals stock?
The technical analysis gauge below displays real-time ratings for the timeframes you select. This is not a recommendation, however. It represents a technical analysis based on the most popular technical indicators: Moving Averages, Oscillators and Pivots. Finder might not concur and takes no responsibility.
This chart is not advice or a guarantee of success. Rather, it gauges the real-time recommendations of three popular technical indicators: moving averages, oscillators and pivots. Finder is not responsible for how your stock performs.
Recursion Pharmaceuticals price performance over time
Historical closes compared with the close of $6.26 from 2025-07-24
1 week (2025-07-18)
7.19%
1 month (2025-06-26)
15.93%
3 months (2025-04-25)
9.25%
6 months (2025-01-24)
-14.60%
1 year (2024-07-26)
-25.03%
2 years (2023-07-26)
-54.07%
3 years (2022-07-26)
7.85
5 years (2020-07-22)
N/A
Recursion Pharmaceuticals financials
Revenue TTM
$59.8 million
Gross profit TTM
$-372,606,016
Return on assets TTM
-38.51%
Return on equity TTM
-86.1%
Profit margin
0%
Book value
$2.30
Market Capitalization
$2.8 billion
TTM: trailing 12 months
Recursion Pharmaceuticals share dividends
We're not expecting Recursion Pharmaceuticals to pay a dividend over the next 12 months.
You may also wish to consider:
Recursion Pharmaceuticals share price volatility
Over the last 12 months, Recursion Pharmaceuticals's shares have ranged in value from as little as $3.79 up to $12.36. A popular way to gauge a stock's volatility is its "beta".
Beta is a measure of a share's volatility in relation to the market. The market (NASDAQ average) beta is 1, while Recursion Pharmaceuticals's is 0.904. This would suggest that Recursion Pharmaceuticals's shares are less volatile than average (for this exchange).
To put Recursion Pharmaceuticals's beta into context you can compare it against those of similar companies.
Recursion Pharmaceuticals, Inc. operates as a clinical-stage biotechnology company, engages in the decoding biology and chemistry by integrating technological innovations across biology, chemistry, automation, data science, and engineering to industrialize drug discovery in the United States. The company develops REC-994, which is in Phase 2 clinical trial to treat cerebral cavernous malformation; REC-2282, which is in Phase 2/3 clinical trial for the treatment of neurofibromatosis type 2; REC-4881, which is in Phase 1b/2 clinical trial to treat familial adenomatous polyposis; REC-3964, which is in Phase 1 clinical trial to treat Clostridioides difficile infection; and REC-4881, which is in Phase 2 clinical trial to treat AXIN1 or APC mutant cancers. Its preclinical stage product includes RBM39 to treat HR-proficient ovarian cancer. The company has collaboration and agreement with Bayer AG; the University of Utah Research Foundation; Ohio State Innovation Foundation; Roche & Genentech; and Takeda Pharmaceutical Company Limited. Recursion Pharmaceuticals, Inc. was incorporated in 2013 and is headquartered in Salt Lake City, Utah.
Frequently asked questions
null What percentage of Recursion Pharmaceuticals is owned by insiders or institutions? Currently 4.776% of Recursion Pharmaceuticals shares are held by insiders and 69.438% by institutions.How many people work for Recursion Pharmaceuticals? Latest data suggests 800 work at Recursion Pharmaceuticals.When does the fiscal year end for Recursion Pharmaceuticals? Recursion Pharmaceuticals's fiscal year ends in December.Where is Recursion Pharmaceuticals based? Recursion Pharmaceuticals's address is: 41 South Rio Grande Street, Salt Lake City, UT, United States, 84101What is Recursion Pharmaceuticals's ISIN number? Recursion Pharmaceuticals's international securities identification number is: US75629V1044What is Recursion Pharmaceuticals's CUSIP number? Recursion Pharmaceuticals's Committee on Uniform Securities Identification Procedures number is: 75629V104
Looking to invest in AI stocks? Here are some of the best artificial intelligence stocks available, along with tips to better understand AI investments.
A deep dive into the highlights and limitations of Robinhood.
Advertiser disclosure
Finder.com is an independent comparison platform and information service that aims to provide you with the tools you need to make better decisions. While we are independent, the offers that appear on this site are from companies from which Finder receives compensation. We may receive compensation from our partners for placement of their products or services. We may also receive compensation if you click on certain links posted on our site. While compensation arrangements may affect the order, position or placement of product information, it doesn't influence our assessment of those products. Please don't interpret the order in which products appear on our Site as any endorsement or recommendation from us. Finder compares a wide range of products, providers and services but we don't provide information on all available products, providers or services. Please appreciate that there may be other options available to you than the products, providers or services covered by our service.
We update our data regularly, but information can change between updates. Confirm details with the provider you're interested in before making a decision.
How likely would you be to recommend Finder to a friend or colleague?
0
1
2
3
4
5
6
7
8
9
10
Very UnlikelyExtremely Likely
Required
Thank you for your feedback.
Our goal is to create the best possible product, and your thoughts, ideas and suggestions play a major role in helping us identify opportunities to improve.
